4.2 Article

Eventual entrainment of the human circadian pacemaker by melatonin is independent of the circadian phase of treatment initiation: Clinical implications

Journal

JOURNAL OF BIOLOGICAL RHYTHMS
Volume 19, Issue 1, Pages 68-75

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/0748730403259670

Keywords

circadian; human; melatonin; melatonin phase response curve; entrainment; blindness

Funding

  1. NCRR NIH HHS [5 MO1 RR000334, K23RR017636-01] Funding Source: Medline
  2. NIA NIH HHS [R01 AG21826] Funding Source: Medline
  3. NICHD NIH HHS [R01 HD42125] Funding Source: Medline
  4. NIMH NIH HHS [R01 MH56874, R01 MH55703] Funding Source: Medline

Ask authors/readers for more resources

About 15% of the legally blind completely lack light perception. Most of these individuals have abnormally phased circadian rhythms and many free-run. Light treatment is not an option for them. However, melatonin treatment can be highly effective. A daily dose of 0.5 mg of melatonin usually results in entrainment. It has been suggested that treatment in individuals with circadian periods > 24 h should be initiated on the advance zone of the melatonin phase response curve, which was based on findings in which melatonin initiated on the delay zone were less likely to result in entrainment, even though treatment continued across all circadian phases. In the present study, 7 totally blind people started low-dose melatonin treatment (0.5 mg; 1 person was given 0.05 mg) on the delay zone. All entrained as circadian phase free-ran and the advance zone of the melatonin phase response curve coincided with the time of melatonin administration. These results are consistent with studies in other mammals. It does not appear that low-dose melatonin treatment needs to be initiated on the advance zone to induce eventual entrainment in blind people with free-running rhythms > 24 h. Therefore, it is not essential that circadian phase be ascertained before starting low-dose melatonin treatment of blind people.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available